{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:12:35Z","timestamp":1790802755030,"version":"4.1.0"},"reference-count":32,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Invasive infections caused by Candida that are resistant to clinically available antifungals are of increasing concern. Increasing rates of fluconazole resistance in non-albicans Candida species have been documented in multiple countries on several continents. This situation has been further exacerbated over the last several years by Candida auris, as isolates of this emerging pathogen that are often resistant to multiple antifungals. T-2307 is an aromatic diamidine currently in development for the treatment of invasive fungal infections. This agent has been shown to selectively cause the collapse of the mitochondrial membrane potential in yeasts when compared to mammalian cells. In vitro activity has been demonstrated against Candida species, including C. albicans, C. glabrata, and C. auris strains, which are resistant to azole and echinocandin antifungals. Activity has also been reported against Cryptococcus species, and this has translated into in vivo efficacy in experimental models of invasive candidiasis and cryptococcosis. However, little is known regarding the clinical efficacy and safety of this agent, as published data from studies involving humans are not currently available.<\/jats:p>","DOI":"10.3390\/jof7020130","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T16:12:10Z","timestamp":1613146330000},"page":"130","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Review of T-2307, an Investigational Agent That Causes Collapse of Fungal Mitochondrial Membrane Potential"],"prefix":"10.3390","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-5122","authenticated-orcid":false,"given":"Nathan P.","family":"Wiederhold","sequence":"first","affiliation":[{"name":"Fungus Testing Laboratory, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"ref_1","unstructured":"WHO (2020, June 21). Antimicrobial Resistance: Global Report on Surveillance. Available online: http:\/\/www.who.int\/drugresistance\/documents\/surveillancereport\/en\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"ofv163","DOI":"10.1093\/ofid\/ofv163","article-title":"Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008\u20132014","volume":"2","author":"Vallabhaneni","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1128\/JCM.06112-11","article-title":"Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata","volume":"50","author":"Pfaller","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses","volume":"64","author":"Lockhart","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S1473-3099(18)30597-8","article-title":"Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: A molecular epidemiological survey","volume":"18","author":"Chow","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Chowdhary, A., Sharma, C., and Meis, J.F. (2017). Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLOS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006290"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents","volume":"48","author":"Alffenaar","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"805","DOI":"10.4065\/mcp.2011.0247","article-title":"Current Concepts in Antifungal Pharmacology","volume":"86","author":"Lewis","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"a019737","DOI":"10.1101\/cshperspect.a019737","article-title":"Treatment Principles for the Management of Mold Infections","volume":"5","author":"Kontoyiannis","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Klatt, M.E., and Eschenauer, G.A. (2021). Review of Pharmacologic Considerations in the Use of Azole Antifungals in Lung Transplant Recipients. J. Fungi, 7.","DOI":"10.3390\/jof7020076"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.01159-07","article-title":"In Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine","volume":"52","author":"Mitsuyama","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1128\/AAC.05954-11","article-title":"T-2307 Causes Collapse of Mitochondrial Membrane Potential in Yeast","volume":"56","author":"Shibata","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1128\/AAC.00355-10","article-title":"T-2307 Shows Efficacy in a Murine Model of Candida glabrata Infection despite In Vitro Trailing Growth Phenomena","volume":"54","author":"Yamada","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1128\/AAC.48.10.3968-3974.2004","article-title":"DB75, a Novel Trypanocidal Agent, Disrupts Mitochondrial Function in Saccharomyces cerevisiae","volume":"48","author":"Lanteri","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/jac\/dkq177","article-title":"Uptake of T-2307, a novel arylamidine, in Candida albicans","volume":"65","author":"Nishikawa","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/jac\/dkw095","article-title":"T-2307, a novel arylamidine, is transported into Candida albicans by a high-affinity spermine and spermidine carrier regulated by Agp2","volume":"71","author":"Nishikawa","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"18393","DOI":"10.1016\/S0021-9258(19)36975-3","article-title":"Evidence that spermine, spermidine, and putrescine are transported electrophoretically in mitochondria by a specific polyamine uniporter","volume":"267","author":"Toninello","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e00374-19","DOI":"10.1128\/AAC.00374-19","article-title":"The Novel Arylamidine T-2307 Selectively Disrupts Yeast Mitochondrial Function by Inhibiting Respiratory Chain Complexes","volume":"63","author":"Yamashita","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/jac\/dkv398","article-title":"The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata","volume":"71","author":"Wiederhold","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1128\/AAC.04228-14","article-title":"The Novel Arylamidine T-2307 MaintainsIn Vitroand In Vivo Activity against Echinocandin-Resistant Candida albicans","volume":"59","author":"Wiederhold","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wiederhold, N.P., Najvar, L.K., Jaramillo, R., Olivo, M., Patterson, H., Connell, A., Fukuda, Y., Mitsuyama, J., Catano, G., and Patterson, T.F. (2019). The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.02198-19"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/jac\/dkx020","article-title":"In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: An emerging fungal pathogen","volume":"72","author":"Nishikawa","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","unstructured":"CLSI (2017). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, Clinical and Laboratory Standards Institute. [3rd ed.]. Document M38."},{"key":"ref_25","unstructured":"CLSI (2017). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Clinical and Laboratory Standards Institute. [4th ed.]. Document M27."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"E246","DOI":"10.1111\/j.1469-0691.2012.03880.x","article-title":"EUCAST technical note on the EUCAST definitive document EDef 7.2: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)*","volume":"18","author":"Arendrup","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1111\/j.1469-0691.2011.03712.x","article-title":"Comparison of anidulafungin\u2019s and fluconazole\u2019s in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis","volume":"18","author":"Wiederhold","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/jac\/dkz020","article-title":"Efficacy of T-2307, a novel arylamidine, against ocular complications of disseminated candidiasis in mice","volume":"74","author":"Abe","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"587","DOI":"10.5694\/j.1326-5377.1996.tb138654.x","article-title":"Diabetes mellitus associated with pentamidine use in HIV-infected patients","volume":"165","author":"Coyle","year":"1996","journal-title":"Med. J. Aust."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1128\/AAC.50.1.294-297.2006","article-title":"Pentamidine Is Active in a Neutropenic Murine Model of Acute Invasive Pulmonary Fusariosis","volume":"50","author":"Lionakis","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/clinids\/24.5.854","article-title":"A 5-Year Retrospective Review of Adverse Drug Reactions and Their Risk Factors in Human Immunodeficiency Virus\u2014Infected Patients Who Were Receiving Intravenous Pentamidine Therapy for Pneumocystis carinii Pneumonia","volume":"24","author":"Dong","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"480","DOI":"10.7326\/0003-4819-103-3-480_1","article-title":"Pentamidine-Associated Hypotension and Route of Administration","volume":"103","author":"Helmick","year":"1985","journal-title":"Ann. Intern. Med."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/7\/2\/130\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:22:47Z","timestamp":1760160167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/7\/2\/130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["jof7020130"],"URL":"https:\/\/doi.org\/10.3390\/jof7020130","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,11]]}}}